阿托莫西汀
轻躁症
注意缺陷多动障碍
狂躁
再摄取抑制剂
抗抑郁药
5-羟色胺再摄取抑制剂
去甲肾上腺素转运体
心理学
去甲肾上腺素
再摄取
精神科
医学
双相情感障碍
内科学
血清素
多巴胺
心情
哌醋甲酯
焦虑
受体
作者
Sümeyra Elif Kaplan Karakaya,Çiğdem Yektaş,Ali Evren Tufan
出处
期刊:Clinical Neuropharmacology
[Ovid Technologies (Wolters Kluwer)]
日期:2021-03-04
卷期号:44 (3): 101-103
被引量:1
标识
DOI:10.1097/wnf.0000000000000447
摘要
Abstract “Activation syndrome” represents a cluster of symptoms of excessive emotional arousal or behavioral activation, which emerges after the first few weeks of antidepressant treatment or a dose increase and resolves with dose reduction or cessation of treatment. It was reported after treatment with selective serotonin reuptake inhibitor and serotonin-norepinephrine reuptake inhibitor group of agents, but no case of activation syndrome has been reported with the norepinephrine reuptake inhibitor group. Atomoxetine is a norepinephrine reuptake inhibitor and nonstimulant and is used to manage symptoms of attention-deficit/hyperactivity disorder (ADHD). Atomoxetine-related symptoms of mania and hypomania were reported in literature previously. Here, we report a case of activation syndrome arising after atomoxetine (ATX) dose titration in a prepubertal male child with ADHD. Differentiation of activation symptoms from mania/hypomania symptoms after treatment with ATX may be important for the clinicians to manage the adverse effects and understand the risk factors behind activation syndrome with use of ATX in children and adolescents diagnosed with ADHD.
科研通智能强力驱动
Strongly Powered by AbleSci AI